ArticleAnticancer research2013
Fenbendazole as a potential anticancer drug.
Article in Anticancer research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 34 citations in OpenAlex.
- Investigation of Fenbendazole Solubility Using Particle Size Reduction Methods in the Presence of SoluplusPharmaceutics · 2025Article
- Synergistic anti-tumor effect of fenbendazole and diisopropylamine dichloroacetate in immunodeficient BALB/c nude mice transplanted with A549 lung cancer cells.Translational lung cancer research · 2025Article
- Fenbendazole Exhibits Antitumor Activity Against Cervical Cancer Through Dual Targeting of Cancer Cells and Cancer Stem Cells: Evidence from In Vitro and In Vivo Models.Molecules (Basel, Switzerland) · 2025Article
- Exploring the Dissolution, Solid-state Properties, and Long-term Storage Stability of Cryoprotectant-free Fenbendazole Nanoparticles.AAPS PharmSciTech · 2024Article
- Preparation and evaluation of fenbendazole methyl-β-cyclodextrin inclusion complexes.BMC veterinary research · 2024Article
- Fenbendazole Exhibits Differential Anticancer Effects In Vitro and In Vivo in Models of Mouse Lymphoma.Current issues in molecular biology · 2023Article
- Anti-cancer effect of fenbendazole-incorporated PLGA nanoparticles in ovarian cancer.Journal of gynecologic oncology · 2023Article
- Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine.Acta pharmaceutica Sinica. B · 2023Review
- Anticancer Evaluation of Methoxy Poly(Ethylene Glycol)-International journal of nanomedicine · 2023Article
- Fenbendazole Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice via Suppression of Fibroblast-to-Myofibroblast Differentiation.International journal of molecular sciences · 2022Article
- Exceptional Repositioning of Dog Dewormer: Fenbendazole Fever.Current issues in molecular biology · 2022Review
- Review
- Anti-cancer effects of fenbendazole on 5-fluorouracil-resistant colorectal cancer cells.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2022Article
- An Update on the Biologic Effects of Fenbendazole.Comparative medicine · 2022Article
- Double Repositioning: Veterinary Antiparasitic to Human Anticancer.International journal of molecular sciences · 2022Review
- Screening the pandemic response box identified benzimidazole carbamates, Olorofim and ravuconazole as promising drug candidates for the treatment of eumycetoma.PLoS neglected tropical diseases · 2022Article
- Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer.Gynecologic oncology · 2021Article
- Physicochemical, Pharmacokinetic, and Toxicity Evaluation of SoluplusPharmaceutics · 2020Article
- Breast cancer animal models and applications.Zoological research · 2020Review
- Dewormer drug fenbendazole has antiviral effects on BoHV-1 productive infection in cell cultures.Journal of veterinary science · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
BACKGROUND/
aimsTo evaluate the anticancer activity of fenbendazole, a widely used antihelminth with mechanisms of action that overlap with those of the hypoxia-selective nitroheterocyclic cytotoxins/radiosensitizers and the taxanes. MATERIALS AND
methodsWe used EMT6 mouse mammary tumor cells in cell culture and as solid tumors in mice to examine the cytotoxic and antitumor effects of fenbendazole as a single agent and in combination regimens.
resultsIntensive treatments with fenbendazole were toxic to EMT6 cells in vitro; toxicity increased with incubation time and under conditions of severe hypoxia. Fenbendazole did not alter the dose-response curves for radiation or docetaxel; instead, the agents produced additive cytotoxicities. Febendazole in maximally-intensive regimens did not alter the growth of EMT6 tumors, or increase the antineoplastic effects of radiation.
conclusionThese studies provided no evidence that fenbendazole would have value in cancer therapy, but suggested that this general class of compounds merits further investigation.
Indexed as
Identifiers
23393324PMC3580766W1733472905What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.